Targeted Genetics Newswire

Targeted Genetics Newswire

Comprehensive Real-Time News Feed for Targeted Genetics.

Results 1 - 20 of 99 in Targeted Genetics

  1. Zacks Investment Research Upgrades Tecogen Inc. (TGEN) to "Buy"Read the original story w/Photo

    Wednesday Dec 7 | AmericanBankingNews.com

    The firm currently has a $4.50 target price on the stock. Zacks Investment Research's target price would suggest a potential upside of 13.92% from the company's previous close.

    Comment?

  2. Roth Capital Analysts Give AmpliPhi Biosciences (APHB) a $10.00 Price TargetRead the original story w/Photo

    Monday Dec 5 | IntersportsWire

    Shares of AmpliPhi Biosciences ( NASDAQ:APHB ) opened at 0.4701 on Wednesday. The stock's 50 day moving average is $0.18 and its 200 day moving average is $0.20. AmpliPhi Biosciences has a 52-week low of $0.07 and a 52-week high of $0.49. The company's market cap is $5.23 million.

    Comment?

  3. AmpliPhi Biosciences (APHB) PT Set at $10.00 by Roth CapitalRead the original story w/Photo

    Friday Dec 2 | Daily Political

    The brokerage presently has a "buy" rating on the stock. Shares of AmpliPhi Biosciences opened at 0.49 on Wednesday.

    Comment?

  4. AmpliPhi Biosciences (APHB) Given a $10.00 Price Target at Roth CapitalRead the original story w/Photo

    Friday Dec 2 | Daily Political

    The brokerage presently has a "buy" rating on the stock. AmpliPhi Biosciences traded up 0.0000% on Wednesday, hitting $0.5191.

    Comment?

  5. Tecogen to Present at Drexel Hamilton Emerging Growth ConferenceRead the original story

    Wednesday Nov 23 | Customer Interaction Solutions

    Management's initiatives have been delivering strong sales and backlog growth, demonstrated by our current backlog near . With the recent announcement of the acquisition of long-time on-site utility affiliate American DG Energy , the turn toward profitability which was demonstrated by our compelling third quarter results , and the significant progress we are making with our emissions development work, it's an exciting time to be a Tecogen shareholder.

    Comment?

  6. AmpliPhi Biosciences Announces Pricing of Public Offering of Common Stock and WarrantsRead the original story w/Photo

    Thursday Nov 17 | Freshnews

    AmpliPhi Biosciences Corporation , a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics, today announced the pricing of an underwritten public offering of 5,335,000 shares of its common stock and warrants to purchase up to an aggregate of 5,335,000 shares of common stock. Each share of common stock is being sold together with a warrant to purchase one share of common stock at a combined price to the public of $0.75 per share and accompanying warrant.

    Comment?

  7. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Thursday Nov 17 | Business Wire

    Net sales for the first six months... )--AmpliPhi Biosciences Corporation , a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics, today a... )--PVH Corp. today announced that it will release its third quarter 2016 earnings results on Wednesday, November 30, 2016 after the market closes. PVH will spons... )--Research and Markets has announced the addition of the "Farm Machinery Market in India: Business Report 2016" report to their offering.

    Comment?

  8. AmpliPhi Bio prices equity offering; shares down 28% premarketRead the original story w/Photo

    Thursday Nov 17 | Seeking Alpha

    AmpliPhi Biosciences slumps 28% premarket on increased volume in response to its public offering of 5,335,000 shares of common stock and warrants to purchase up to 5,335,000 shares of common at a combined price of $0.75. The five-year warrants are immediately exercisable at $0.75.

    Comment?

  9. AmpliPhi Bio Announces Settlement Of Pending LawsuitRead the original story

    Sunday Nov 13 | BioSpace

    AmpliPhi Biosciences Corporation , a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced the settlement of its pending lawsuit with NRM VII Holdings I, LLC . The lawsuit relates to a complaint filed by NRM against AmpliPhi and the members of its board of directors following the automatic conversion of NRM's Series B convertible preferred stock into common stock of AmpliPhi in April 2016.

    Comment?

  10. AmpliPhi Biosciences Announces Settlement of Pending LawsuitRead the original story w/Photo

    Monday Nov 14 | Freshnews

    AmpliPhi Biosciences Corporation , a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced the settlement of its pending lawsuit with NRM VII Holdings I, LLC . The lawsuit relates to a complaint filed by NRM against AmpliPhi and the members of its board of directors following the automatic conversion of NRM's Series B convertible preferred stock into common stock of AmpliPhi in April 2016.

    Comment?

  11. AmpliPhi Biosciences Sweetens Follow-On Offering TermsRead the original story w/Photo

    Sunday Nov 13 | Seeking Alpha

    AmpliPhi Biosciences has registered 5.3 million shares of its common stock for sale in a follow-on offering. The company previously filed an S-1 registration statement for the 5.3 million share offering along with 25% warrant coverage of 1.325 million shares.

    Comment?

  12. AmpliPhi Bio Reports Third Quarter 2016 Financial Results And Provides Corporate UpdateRead the original story

    Thursday Nov 10 | BioSpace

    November 10, 2016 - AmpliPhi Biosciences Corporation , a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced financial results for the third quarter ended September 30, 2016. "AmpliPhi has made tremendous progress this quarter, demonstrated by the announcement of topline data from clinical trials of both of our lead development programs, including the first U.S.-based trial of AB-SA01," said M. Scott Salka, CEO of AmpliPhi Biosciences.

    Comment?

  13. Tecogen Inc. (TGEN) Announces Earnings ResultsRead the original story w/Photo

    Friday Nov 11 | Daily Political

    Tecogen Inc. released its quarterly earnings data on Thursday. The company reported $0.01 EPS for the quarter, beating the consensus estimate of by $0.05.

    Comment?

  14. AmpliPhi Biosciences Reports Third Quarter 2016 Financial Results and Provides Corporate UpdateRead the original story

    Thursday Nov 10 | Customer Interaction Solutions

    AmpliPhi Biosciences Corporation , a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced financial results for the third quarter ended September 30, 2016. "AmpliPhi has made tremendous progress this quarter, demonstrated by the announcement of topline data from clinical trials of both of our lead development programs, including the first U.S.-based trial of AB-SA01," said M. Scott Salka, CEO of AmpliPhi Biosciences.

    Comment?

  15. Tecogen Inc. (TGEN) Issues Earnings ResultsRead the original story

    Thursday Nov 10 | AmericanBankingNews.com

    Tecogen Inc. released its quarterly earnings results on Thursday. The company reported $0.01 EPS for the quarter, topping the consensus estimate of by $0.05.

    Comment?

  16. AmpliPhi Bio Granted Small And Medium Enterprise Status By EMARead the original story

    Oct 31, 2016 | BioSpace

    AmpliPhi Biosciences Corporation , a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced that it has been granted Small and Medium Enterprise designation by the European Medicines Agency . "We expect Europe to be a key market for AmpliPhi and our phage-based therapies to treat bacterial infections in patients with unmet medical needs" SME designation was launched by the EMA to promote innovation and the development of new human therapeutics by early and mid-stage healthcare companies.

    Comment?

  17. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Nov 1, 2016 | Business Wire

    Global Smart Inhalers Market Worth USD 191 Million by 2022 - Analysis, Technologies & Forecasts Report 2014-2022 - Vendors: Propeller Health, Novartis, Vectura Group - Research and Markets )--Research and Markets has announced the addition of the "Smart Inhalers Market by Product , Metered Dose Inhalers )... Two Day Design of Experiments for Process/Product Optimization Course - Los Angeles, CA, United States - November 10th-11th, 2016 - Research and Markets )--Research and Markets has announced the addition of the "Design of Experiments for Process/Product Optimization" conference to their offering. This course is designed to hel... )--FelCor Lodging Trust Incorporated today reported results for the third quarter ended September 30, 2016.

    Comment?

  18. AmpliPhi Bio Announces Favorable Topline Safety And Tolerability...Read the original story

    Oct 24, 2016 | BioSpace

    AmpliPhi Biosciences Corporation , a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced topline results from its Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus infections in patients suffering from chronic rhinosinusitis . Enrollment in the trial has been completed and the Safety Monitoring Committee overseeing the trial has determined that AB-SA01 was well-tolerated by all nine patients and that there were no drug-related serious adverse events.

    Comment?

  19. AmpliPhi Biosciences Announces Favorable Topline Safety and...Read the original story

    Oct 25, 2016 | Customer Interaction Solutions

    AmpliPhi Biosciences Corporation , a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced topline results from its Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus infections in patients suffering from chronic rhinosinusitis . Enrollment in the trial has been completed and the Safety Monitoring Committee overseeing the trial has determined that AB-SA01 was well-tolerated by all nine patients and that there were no drug-related serious adverse events.

    Comment?

  20. AmpliPhi Biosciences Appoints Dr. Carrie-Lynn Langlais Furr as Vice...Read the original story w/Photo

    Oct 17, 2016 | Freshnews

    AmpliPhi Biosciences Corporation , a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced that Carrie-Lynn Langlais Furr, Ph.D., RAC, has been appointed as the Company's Vice President of Regulatory Affairs and Program Management. In addition to more than 16 years of scientific expertise in bacteriophage, Dr. Furr brings over a decade of integrated product development and regulatory affairs experience to this new position at AmpliPhi.

    Comment?